Minerva Neurosciences | NERV - Bénéfice Avant Impôts





Bénéfice Avant Impôts Changement Date
Acadia Pharmaceuticals USD 46.47M 42.49M 2026-06
Adma Biologics USD 57.13M 4.47M 2026-03
ALKERMES USD -61.93M 122.3M 2026-03
Alterity Therapeutics Limited AUD -6.26M 1.52M 2025-12
AstraZeneca USD 4.81B 894M 2026-06
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Bristol-Myers Squibb USD 4.99B 1.75B 2026-06
Cipla INR 10.82B 3.33B 2026-06
Clal Biotechnology ILS 86.82M 17.9M 2022-12
Compugen USD -7.66M 64.51M 2026-03
CSL USD 2.61B 1.21B 2025-12
Eli Lilly USD 8.85B 583.8M 2026-03
GlaxoSmithKline GBP 2.68B 532M 2026-06
Grifols EUR 257.85M 190.87M 2024-12
Halozyme Therapeutics USD 180.33M 281.18M 2026-03
Ionis Pharmaceuticals USD -114M 21M 2026-06
J&J USD 8.66B 839M 2026-06
Merck USD -3.53B 6.95B 2026-03
Minerva Neurosciences USD 22.51M 30.74M 2024-09
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Novartis USD 4.27B 430M 2026-06
Novavax USD 17.9M 220.94M 2025-12
Pfizer USD -653M 5.84B 2026-06
Roche Holding CHF 11.17B 6.38B 2026-06
Sanofi EUR 837M 1.17B 2026-06
Takeda JPY 162.72B 215.2B 2026-06
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12